- Home
- GNLN vs ONCO Comparison
GNLN vs ONCO Comparison
Compare GNLN & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLN
- ONCO
- Stock Information
- Founded
- GNLN 2005
- ONCO 2018
- Country
- GNLN United States
- ONCO United States
- Employees
- GNLN N/A
- ONCO N/A
- Industry
- GNLN Durable Goods
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- GNLN Consumer Discretionary
- ONCO Health Care
- Exchange
- GNLN Nasdaq
- ONCO Nasdaq
- Market Cap
- GNLN 1.6M
- ONCO 1.8M
- IPO Year
- GNLN 2019
- ONCO 2022
- Fundamental
- Price
- GNLN $0.29
- ONCO $0.07
- Analyst Decision
- GNLN
- ONCO
- Analyst Count
- GNLN 0
- ONCO 0
- Target Price
- GNLN N/A
- ONCO N/A
- AVG Volume (30 Days)
- GNLN 388.7K
- ONCO 9.2M
- Earning Date
- GNLN 03-21-2025
- ONCO 05-19-2025
- Dividend Yield
- GNLN N/A
- ONCO N/A
- EPS Growth
- GNLN N/A
- ONCO N/A
- EPS
- GNLN N/A
- ONCO N/A
- Revenue
- GNLN $13,275,000.00
- ONCO $1,870,605.00
- Revenue This Year
- GNLN $1,541.21
- ONCO N/A
- Revenue Next Year
- GNLN N/A
- ONCO N/A
- P/E Ratio
- GNLN N/A
- ONCO N/A
- Revenue Growth
- GNLN N/A
- ONCO N/A
- 52 Week Low
- GNLN $0.26
- ONCO $0.07
- 52 Week High
- GNLN $21.80
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- GNLN 21.61
- ONCO 17.45
- Support Level
- GNLN $0.26
- ONCO $0.07
- Resistance Level
- GNLN $0.37
- ONCO $0.15
- Average True Range (ATR)
- GNLN 0.05
- ONCO 0.02
- MACD
- GNLN 0.01
- ONCO 0.01
- Stochastic Oscillator
- GNLN 10.83
- ONCO 9.41
About GNLN Greenlane Holdings Inc.
Greenlane Holdings Inc is a distributor of vaporization products and consumption accessories in the United States. It offers a selection of stock-keeping units including vaporizers and parts, cleaning products, grinders and storage containers, pipes, rolling papers and customized lines of premium specialty packaging. The company markets and sells its products in both the business to business and business to consumer sectors of the marketplace. Its geographical segment includes the United States; Canada and Europe. It derives a majority of revenue from the United States.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.